Sanara MedTech develops and markets surgical and wound care products including CellerateRX Surgical collagen for wound management, BIASURGE surgical irrigation solutions and FORTIFY tissue repair grafts. The company also offers bone graft substitutes, amniotic membrane allografts and antimicrobial wound products. These are sold to hospitals, clinics and post-acute providers to support better surgical and healing outcomes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 25.8 | — | -2 | — |
| Q3 2025 | 26.3 | — | -30.4 | — |
| Q4 2025 | 27.6 | — | -1.6 | — |
| Q1 2026 | 27.8 | — | 0.5 | — |
| Q2 2026 | 28.1 | 9% | -0.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Montauk Renewables, Inc. (MNTK), Bitcoin Infrastructure Acquisition Corp Ltd. (BIXI), OTG Acquisition Corp. I (OTGA), Highview Merger Corp. (HVMC), NI Holdings, Inc. (NODK), GSR V Acquisition Corp. (GSRV)